Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in non-atopic (“intrinsic”) asthma
2009-009154-25Phase 3Terminated
- Sponsor
- King's College London
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of omalizumab in asthma, sponsored by King's College London. Primary endpoint: Primary endpoint (first 12 weeks prior to therapy reduction). Started May 2009; status: terminated.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2009-009154-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009154-25.